Fourteen-Day Gemcitabine-Docetaxel Chemotherapy Is Effective and Safer Compared to 21-Day Regimen in Patients with Advanced Soft Tissue and Bone Sarcoma
Gemcitabine-docetaxel (G-D) combination is an effective chemotherapy for patients with advanced soft tissue and bone sarcoma, first developed with G administered on days 1 and 8, and D on day 8 every 21 days and later modified to be administered every 14 days in 2012. The 14-day regimen has become i...
Main Authors: | Minggui Pan, Maily K. Trieu, Manpreet Sidhu, Jeanette Yu, Tiffany Seto, Kristen Ganjoo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/8/1983 |
Similar Items
-
Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
by: Jie Xu, et al.
Published: (2018-10-01) -
Gemcitabine and Docetaxel as a Second-Line Treatment in Advanced Soft Tissue Sarcomas
by: Hend Ahmed El-Hadaad, et al.
Published: (2011-09-01) -
Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study
by: Hitomi Hara, et al.
Published: (2019-07-01) -
A comparison of neoadjuvant chemotherapy with gemcitabine versus docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis
by: Liu T, et al.
Published: (2018-11-01) -
The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine
by: Elisabeth S Stovgaard, et al.
Published: (2021-01-01)